PolarityTE, Inc. Overview
Pro stress-test →PolarityTE is a clinical-stage biotechnology company developing regenerative tissue products and biomaterials, focused on transforming the lives of patients by discovering, designing, and developing regenerative tissue products for the fields of medicine, biomedical engineering, and material sciences. The company was acquired by Grander Acquisition LLC (an entity led by Michael Brauser) in August 2023, and continues operations under the PolarityTE name as a private company.
Strategic Profile
Pro stress-test →The flagship product, SkinTE, is used for repair, reconstruction, replacement, or regeneration of the skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. SkinTE has received Breakthrough Therapy Designation (BTD) from the FDA for the treatment of Wagner Grade 1 Diabetic Foot Ulcers (DFU), positioning the company for accelerated regulatory pathways. Final completion and last patient visit are expected by November 2025, with top-line results anticipated in the first quarter of 2026.
Competitive Landscape
Pro stress-test →Organogenesis Holdings is among PolarityTE's competitors in the regenerative medicine and wound care space. The company competes against established wound care manufacturers and emerging cellular therapy platforms, with differentiation through autologous heterogeneous skin construct technology and FDA breakthrough designation.
Industry Context
PolarityTE, Inc. operates in Regenerative tissue engineering and wound healing.
Key facts
Founded: 2016 · Headquarters: Salt Lake City, US · Employees: 22 · Revenue: $3.8M